Mehmet Ali Sekeroglu1, Emre Hekimoglu2, Yasemin Tasci3, Ismail Dolen3, Umut Arslan4. 1. a Ophthalmology Department, Ulucanlar Eye Training and Research Hospital , Ankara , Turkey . 2. b Ophthalmology Department and. 3. c Urogynecology Department, Etlik Zubeyde Hanim Maternity and Research Hospital , Ankara , Turkey , and. 4. d Biostatistics Department, Hacettepe University Faculty of Medicine , Ankara , Turkey.
Abstract
OBJECTIVE: To investigate the effect of oral solifenacin succinate on Schirmer I test results, tear break-up time (TBUT) and Ocular Surface Disease Index (OSDI) scores in overactive bladder (OAB) patients and to compare these results with those of healthy control subjects. MATERIALS AND METHODS: The female OAB patients who were prescribed oral solifenacin succinate 5 mg/day (Group I, N = 80) and age-matched healthy female subjects (Group II, N = 40) were recruited for the study and underwent ophthalmological examination prior to oral treatment and after 4 weeks. They completed the OSDI questionnaire and underwent ocular surface tests including Schirmer I test and TBUT. RESULTS: The statistical analysis of the Schirmer I test and TBUT revealed no significant difference between the baseline and 4th week values in both groups (Group I, p = 0.506 and p = 0.070 consecutively) (Group II, p = 0.810 and p = 0.823 consecutively). OSDI scores were found to be significantly increased in group I (21.8 ± 4.2 vs 23.1 ± 4.6, p = 0.020) and remained unchanged in group II (20.5 ± 7.0 vs 20.7 ± 7.0, p = 0.805). CONCLUSIONS: Short-term solifenacin succinate treatment has no effect on the Schirmer I test results and TBUT, but ocular surface symptoms appeared to be exacerbated in respect with increased OSDI scores. However, the clinical significance needs to be further evaluated with larger studies.
OBJECTIVE: To investigate the effect of oral solifenacin succinate on Schirmer I test results, tear break-up time (TBUT) and Ocular Surface Disease Index (OSDI) scores in overactive bladder (OAB) patients and to compare these results with those of healthy control subjects. MATERIALS AND METHODS: The female OABpatients who were prescribed oral solifenacin succinate 5 mg/day (Group I, N = 80) and age-matched healthy female subjects (Group II, N = 40) were recruited for the study and underwent ophthalmological examination prior to oral treatment and after 4 weeks. They completed the OSDI questionnaire and underwent ocular surface tests including Schirmer I test and TBUT. RESULTS: The statistical analysis of the Schirmer I test and TBUT revealed no significant difference between the baseline and 4th week values in both groups (Group I, p = 0.506 and p = 0.070 consecutively) (Group II, p = 0.810 and p = 0.823 consecutively). OSDI scores were found to be significantly increased in group I (21.8 ± 4.2 vs 23.1 ± 4.6, p = 0.020) and remained unchanged in group II (20.5 ± 7.0 vs 20.7 ± 7.0, p = 0.805). CONCLUSIONS: Short-term solifenacin succinate treatment has no effect on the Schirmer I test results and TBUT, but ocular surface symptoms appeared to be exacerbated in respect with increased OSDI scores. However, the clinical significance needs to be further evaluated with larger studies.
Entities:
Keywords:
Dry eye; Schirmer test; ocular surface; tear break-up time
Authors: Ali Riza Turkoglu; Neslihan Parmak Yener; Soner Coban; Muhammet Guzelsoy; Murat Demirbas; Hakan Demirci Journal: Int Urogynecol J Date: 2016-11-14 Impact factor: 2.894
Authors: William B Trattler; Parag A Majmudar; Eric D Donnenfeld; Marguerite B McDonald; Karl G Stonecipher; Damien F Goldberg Journal: Clin Ophthalmol Date: 2017-08-07